Search Results

inconsistent reporting of response criteria and methods for mPFS and mOS. Conclusion: ICI retreatment is used in clinical practice; however, our systematic literature review found no randomized trials supporting the use of ICI after anti–PD-1. Limited

reporting adverse events (AE) were excluded. All AEs were reported for phase II trials, while toxicities occurring up to the maximally tolerated dose (MTD) were noted for patients in phase I dose-escalation trials. Results were pooled via Review Manager v5

JI . Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases . Am J Surg Pathol 2006 ; 30 : 883 – 891 . 33 Zincke H Utz DC Farrow GM . Review of Mayo Clinic experience with carcinoma in situ

clearly and effectively explained.” The objective of the IOM's recommendation was to promote care coordination, communication, and record-keeping efficiency. Although there are other survivors with active disease, this review focuses on patients ending

need. We reviewed published literature to assess the clinical performance of various interventions in newly diagnosed GBM by MGMT methylation status. Methods: An SLR was conducted from database inception through October 29, 2018, in accordance with

for advanced renal cell carcinoma (aRCC). When used individually, both ICIs and VEGFis have significant mucocutaneous toxicities. We performed a systematic review and meta-analysis of phase 3 randomized controlled trials (RCTs) to determine the

Controlled Trials of Long-Term Outcomes A systematic review recently reported on randomized controlled trials in adult patients with solid tumors or lymphoma undergoing systemic chemotherapy with or without primary G-CSF support with a follow-up of at least

in mRCC and characterize outcomes in this specific patient population. Patients and Methods After obtaining Institutional Review Board approval at Gustave Roussy and Memorial Sloan Kettering Cancer Center, a retrospective multicenter chart

survival with maintenance thalidomide. (A) All trials. (B) Excluding Barlogie 2006. Abbreviations: HR, hazard ratio; OS, overall survival; SE, standard error. Adapted from Hicks LK, Haynes AE, Reece DE, et al. A meta-analysis and systematic review of

compared with the general population. To ascertain study eligibility, a genetic counselor (A. Cuggia) obtained a personal and, at minimum, a 3-generation family history and verified clinical diagnoses through review of medical records. Participants were